Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service hysterectomy, hysteroscopy & ablation cases in Nebraska: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (238 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 7 | 641 | 18% |
| 2020 | 4 | 573 | 22% |
| 2021 | 5 | 565 | 27% |
Laparoscopic/robotic hysterectomy, hysteroscopic resection, endometrial ablation. Professional codes (what the surgeon bills): CPT 58571, 58573, 58558, 58563, 58353, 58356, 58661, 58662.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Nebraska; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 35 | 1,512−0.1%/yr | −0.1%/yr | 5.81.1× | 12% | 1,880 in 2030+3.7%/yr |
| BPH procedures |
Hysterectomy, hysteroscopy & ablation in every state, and its device makers · Every procedure market in Nebraska · Every state · Compare with Illinois
| 2024 |
| 529 |
| 37% |
| 2025 est. | ≈ 600 | – |
| 2026 est. | ≈ 610 | – |
| 2022 | 7 | 572 | 31% |
| 2023 | 5 | 551 | 35% |
| 2024 | 4 | 529 | 37% |
| 2025 from claims | – | 602 487–707 | 37% |
| 2026 forecast | – | 615 482–772 | 37% |
| 2027 forecast | – | 624 463–825 | 37% |
| 2028 forecast | – | 633 448–874 | 38% |
| 2029 forecast | – | 643 437–922 | 38% |
| 2030 forecast | – | 652 427–968 | 38% |
In 2025, 3% inpatient hospital, 88% hospital outpatient, 9% surgery center.
| −0.8%/yr |
| 3.1 |
| 7% |
| 3,530 in 2030+2%/yr |
| Michigan | 15 | 2,577−6%/yr | −6%/yr | 3.4 | 11% | 2,550 in 2030−0.1%/yr |
| Indiana | 18 | 2,015−2.6%/yr | −2.6%/yr | 3.1 | 13% | 2,050 in 2030+0.2%/yr |
| Missouri | 13 | 1,625−3.4%/yr | −3.4%/yr | 2.9 | 10% | 1,650 in 2030+0.2%/yr |
| Wisconsin | 12 | 1,602−0.7%/yr | −0.7%/yr | 3.1 | 7% | 1,910 in 2030+3%/yr |
| Minnesota | 18 | 1,547−1%/yr | −1%/yr | 3.8 | 9% | 2,280 in 2030+6.7%/yr |
| Iowa | 12 | 908−1.5%/yr | −1.5%/yr | 2.2 | 11% | 880 in 2030−0.4%/yr |
| Kansas | 14 | 868−1.5%/yr | −1.5%/yr | 2.3 | 11% | 890 in 2030+0.4%/yr |
| South Dakota | 2 | 342−0.3%/yr | −0.3%/yr | 2.8 | 0% | 380 in 2030+1.9%/yr |
| North Dakota | 1 | 216−1.3%/yr | −1.3%/yr | 2.3 | 10% | 220 in 2030+0.5%/yr |
| 20 |
| 1,469−17%/yr |
| −17%/yr |
| 5.61.2× |
| 29% |
| 1,250 in 2030−2.7%/yr |
| Incontinence, prolapse & sacral neuromodulation | 12 | 849−2%/yr | −2%/yr | 3.21.5× | 24% | 1,020 in 2030+3.1%/yr |
| Prostatectomy & nephrectomy | 9 | 452+0.8%/yr | +0.8%/yr | 1.81.3× | 0% | 520 in 2030+2.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Hologic Sales And Service leads with 89% of company spending on these surgeons in 2025, +32 pts on 2024.
In 2025, 2 companies reported engagement with Nebraska’s surgeons worth $2,563 in consulting, speaking, meals and travel tied to these products, about $641 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.